|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes : protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International
Title: | Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes : protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study |
Authors: | Kameda, Reina Browse this author | Nomoto, Hiroshi Browse this author | Cho, Kyu Yong Browse this author | Kawata, Shinichiro Browse this author | Omori, Kazuno Browse this author | Takeuchi, Jun Browse this author | Nagai, So Browse this author →KAKEN DB | Kurihara, Yoshio Browse this author | Aoki, Shin Browse this author | Nakamura, Akinobu Browse this author →KAKEN DB | Atsumi, Tatsuya Browse this author →KAKEN DB | Miyoshi, Hideaki Browse this author →KAKEN DB |
Issue Date: | Feb-2020 |
Publisher: | BMJ Publishing Group |
Journal Title: | BMJ Open |
Volume: | 10 |
Issue: | 2 |
Start Page: | e034883 |
Publisher DOI: | 10.1136/bmjopen-2019-034883 |
Abstract: | Introduction Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events. We aim to test the hypothesis that the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, ameliorates nocturnal hypertension more effectively than a dipeptidyl peptidase (DPP)-4 inhibitor in patients with T2D. Methods and analysis This study is a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group trial. Sixty participants with T2D and hypertension who have been treated with a DPP-4 inhibitor for more than 4 weeks and who have a glycated haemoglobin A1c (HbA1c) level of 6.0%-9.0% will be randomised based on age, body mass index (BMI) and HbA1c to continue taking their DPP-4 inhibitor or to switch to luseogliflozin 2.5 mg once daily for 8 weeks. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) will be performed twice at baseline and at the end of the study. All participants will continue their diet and exercise therapy, and the doses of concomitant medications will not be adjusted during the study. The primary endpoint is the effect of luseogliflozin on the mean change in systolic blood pressure (SBP) during the night, as measured by ABPM. The secondary endpoints are mean change in diastolic blood pressure (DBP) during the night, 24 hours of SBP and DBP, daytime SBP and DBP, pulse rate, BP M-value, trough SBP and DBP for 1 hour before the next dose, and other laboratory parameters. The sample size was calculated for a two-sided test at 90% power for the detection of a difference between treatments. Ethics and dissemination The Ethics Review Board of Hokkaido University Hospital has approved the protocol. The results will be disseminated in peer-reviewed journals and at scientific conferences. |
Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/78557 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|